Median (Q1, Q3) site-level baseline hazard estimate | p-value for non-zero variance | |
---|---|---|
Death or lung transplant | 0.98 (0.92, 1.11) | 0.28 |
Hospitalization | 1.06 (0.77, 1.30) | 0.052 |
Decline in FVC ≥ 10% (mL) or death or lung transplant | 0.99 (0.94, 1.03) | 0.29 |
Decline in FVC ≥ 10% predicted or death or lung transplant | 1.00 (0.97, 1.02) | 0.52 |
Decline in DLco ≥ 15% (mmol/min/kPa) or death or lung transplant | 0.97 (0.94, 1.07) | 0.11 |
Decline in DLco ≥ 15% predicted or death or lung transplant | 0.99 (0.90, 1.13) | 0.12 |
Increase in SGRQ total score ≥ 7 or death or lung transplant | 0.99 (0.98, 1.01) | 0.48 |
Increase in SGRQ activity score ≥ 5 or death or lung transplant | 0.99 (0.97, 1.03) | 0.40 |
Increase in SGRQ impact score ≥ 7 or death or lung transplant | 0.99 (0.97, 1.01) | 0.40 |
Increase in SGRQ symptoms score ≥ 8 or death or lung transplant | 0.99 (0.91, 1.02) | 0.20 |
Decrease in CASA-Q cough impact domain ≥ 11 or death or lung transplant | 0.99 (0.94, 1.05) | 0.23 |
Decrease in CASA-Q cough symptoms domain ≥ 11 or death or lung transplant | 0.98 (0.91, 1.06) | 0.13 |
Decrease in EuroQoL-5D index score ≥ 0.06 or death or lung transplant | 1.00 (0.98, 1.01) | 0.72 |
Decrease in EuroQoL-5D VAS score ≥ 8 or death or lung transplant | 1.00 (0.97, 1.03) | 0.60 |
Decrease in SF-12 MCS score ≥ 6 or death or lung transplant | 0.99 (0.95, 1.05) | 0.32 |
Decrease in SF-12 PCS score ≥ 5 or death or lung transplant | 0.99 (0.98, 1.01) | 0.54 |